Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin's Lymphoma

Sep 24, 2026

Uploaded by Jiven

B-cell non-Hodgkin's lymphomas show wide histological and clinical heterogeneity, making diagnostic decisions complex and emphasizing the need for early detection. Timely interventions for destructive subtypes can improve outcomes, but current biomarkers remain insufficient. This review explains how metabolomics—profiling all metabolites in the human body—links a patient phenotype to clinically useful biomarkers for diagnosis, severity assessment, and prognosis. It outlines metabolomics workflows and compares key technique advantages and limitations, including predictive metabolic biomarkers and future therapeutic discovery potential.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages17

Reading Time43 min

AccessFree to download

Introduction

Metabolomics and diagnostic relevance

Metabolomics workflows and techniques

Predictive metabolic biomarkers for diagnosis and prognosis

Benefits and drawbacks of approaches

Future perspectives

diagnostics Review Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin's Lymphoma Abdullah Alfaiﬁ 1,2, Mohammed Y. Refai 3, Mohammed Alsaadi 1,4, Salem Bahashwan 4,5,6, Haﬁz Malhan 7, Waiel Al-Kahiry 7, Enas Dammag 7, Ageel Ageel 7, Amjed Mahzary 8, Raed Albiheyri 1, Hussein Almehdar 1 and Ishtiaq Qadri 1, * Citation: Alfaiﬁ, A.; Refai, M.Y.; Alsaadi, M.; Bahashwan, S.; Malhan, H.; Al-Kahiry, W.; Dammag, E.; Ageel, A.; Mahzary, A.; Albiheyri, R.; et al. Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin's Lymphoma. Diagnostics 2023, 13, 861. [https://](https://)[ ](https://)[doi.org/10.3390/diagnostics](doi.org/10.3390/diagnostics)[ ](doi.org/10.3390/diagnostics)13050861 Academic Editor: Sayed Sartaj Sohrab Received: 20 January 2023 Revised: 19 February 2023 Accepted: 22 February 2023 Published: 23 February 2023 Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) . 1 Department of Biological Science, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia 2 Fayfa General Hospital, Ministry of Health, Jazan 83581, Saudi Arabia 3 Department of Biochemistry, College of Science, University of Jeddah, Jeddah 21493, Saudi Arabia 4 Hematology Research Unit, King Fahad Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia 5 Department of Hematology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia 6 King Abdulaziz University Hospital, King Abdulaziz University, Jeddah 21589, Saudi Arabia 7 Prince Mohammed Bin Nasser Hospital, Ministry of Health, Jazan 82943, Saudi Arabia 8 Eradah Hospital, Ministry of Health, Jazan 82943, Saudi Arabia * Correspondence: [ishtiaq80262@yahoo.com](ishtiaq80262@yahoo.com) Abstract: A wide range of histological as well as clinical properties are exhibited by B-cell nonHodgkin's lymphomas. These properties could make the diagnostics process complicated. The diagnosis of lymphomas at an initial stage is essential because early remedial actions taken against destructive subtypes are commonly deliberated as successful and restorative. Therefore, better protective action is needed to improve the condition of those patients who are extensively affected by cancer when diagnosed for the ﬁrst time. The development of new and efﬁcient methods for early detection of cancer has become crucial nowadays. Biomarkers are urgently needed for diagnosing B-cell non-Hodgkin's lymphoma and assessing the severity of the disease and its prognosis. New possibilities are now open for diagnosing cancer with the help of metabolomics. The study of all the metabolites synthesised in the human body is called “metabolomics.” A patient's phenotype is directly linked with metabolomics, which can help in providing some clinically beneﬁcial biomarkers and is applied in the diagnostics of B-cell non-Hodgkin's lymphoma. In cancer research, it can analyse the cancerous metabolome to identify the metabolic biomarkers. This review provides an understanding of B-cell non-Hodgkin's lymphoma metabolism and its applications in medical diagnostics. A description of the workﬂow based on metabolomics is also provided, along with the beneﬁts and drawbacks of various techniques. The use of predictive metabolic biomarkers for the diagnosis and prognosis of B-cell non-Hodgkin's lymphoma is also explored. Thus, we can say that abnormalities related to metabolic processes can occur in a vast range of B-cell non-Hodgkin's lymphomas. The metabolic biomarkers could only be discovered and identiﬁed as innovative therapeutic objects if we explored and researched them. In the near future, the innovations involvi

FAQs

Why is early diagnosis important for B-cell non-Hodgkin's lymphoma?

Early detection is essential because prompt actions against destructive subtypes are often considered more successful and restorative, improving outcomes for patients diagnosed at first presentation.

How does metabolomics support diagnosis and prognosis in B-cell non-Hodgkin's lymphoma?

Metabolomics evaluates metabolites in cells, tissues, and body fluids, linking patient phenotype to metabolism and enabling identification of clinically beneficial biomarkers for diagnosis, severity, and prognosis.

What does this review cover about metabolomics methods?

The review provides an understanding of B-cell non-Hodgkin's lymphoma metabolism, describes metabolomics workflows, and discusses benefits and drawbacks of various techniques, including use of predictive metabolic biomarkers.

Sep 24, 2026

Uploaded by Jiven